Private equity firm GHO Capital Partners has appointed David W. Miller and Geoffrey Hamilton-Fairley as operating partners.
Miller was formerly senior vice president of global market access at biotechnology company Biogen, responsible for pricing and reimbursement of six global product launches.
He also founded his own advisory practice, Miller Pharma and is a board observer to AI company GNS Healthcare.
Hamilton-Fairley has extensive experience of investing in, and leading companies at different stages of development from start-ups through to sale and IPO, with particular experience within medtech and advanced therapies.
His experience includes developing and guiding Oncimmune, a company focusing on early cancer detection technology, from a Nottingham University start-up through to a successful IPO in May 2016.
‘GHO is unquestionably the reference player in European healthcare. I am delighted to have the opportunity to work with their portfolio, who represent some of the industry’s fastest growing, most innovative and highest quality companies in the market today,’ said Miller.
‘With the world’s spotlight increasingly on healthcare and life sciences, the GHO team has already shown it targets the best opportunities and guides them with expertise to expedite their progress. I am looking forward to bringing together promising companies in medtech and advanced therapeutics with the capital and guidance they need to further enhance the GHO portfolio,’ Hamilton-Fairley added.